Experimental lymphoma drug trial halted early after only 8 patients
NCT ID NCT04362007
First seen Mar 22, 2026 · Last updated May 25, 2026 · Updated 9 times
Summary
This study tested an experimental drug called ASTX660 in people with T-cell lymphoma that had returned or stopped responding to other treatments. The goal was to find a safe dose and see if the drug could help control the cancer. Only 8 people took part before the study was stopped early, so we don't have clear results on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yamagata University Hospital
Yamagata, Japan
Conditions
Explore the condition pages connected to this study.